Our Take
This is vendor content about established biotech methods, not a new capability or benchmark—promotional framing without evidence of a measurable advance.
Why it matters
mRNA drug development remains capital-intensive and time-consuming; any tooling that reduces cycle time from screening to candidate nomination directly affects portfolio economics and competitive speed in a crowded space.
Do this week
Drug discovery leads: audit your current RT-qPCR throughput and transcriptomics pipeline against vendor-neutral benchmarks (SEQC, ENCODE standards) before committing to a single platform.
Vendor positions high-throughput RT-qPCR and transcriptomics in mRNA discovery
Evotec, a contract research organization, has published resource material on the application of high-throughput reverse-transcription quantitative PCR (RT-qPCR) and transcriptomics methods in mRNA-driven drug discovery. The resource positions these techniques as capable of delivering scalable insights across screening, candidate nomination, and downstream phases of drug development.
RT-qPCR is a long-established method for quantifying gene expression at scale. Transcriptomics analysis measures expression across thousands of genes in parallel. Neither technique is novel, but the framing here centers on their application within integrated workflows for mRNA therapeutics development, where rapid phenotypic and molecular characterization can accelerate candidate selection.
Speed and throughput directly drive portfolio economics in mRNA drug discovery
mRNA programs consume significant research capital before reaching the clinic. Extended screening phases and ambiguous candidate nomination increase both sunk cost and time-to-decision. Tools that reduce cycle time from initial screening to nominated candidates can lower per-program burn, compress calendar time, and allow teams to run broader experimental branches in parallel.
Transcriptomics-informed selection of mRNA constructs or delivery formulations can also reduce downstream failures by incorporating mechanistic readouts earlier in the development path, rather than relying solely on cell viability or protein expression assays. The value is conditional on integration: standalone RT-qPCR or transcriptomics data generates noise without a clear decision rule.
Validate method and platform choices against your discovery questions
If you own mRNA candidate selection, do not assume that high-throughput capacity alone improves decision quality. Confirm three things: (1) the assay actually predicts your downstream phenotype of interest (oncology, immunogenicity, liver safety, etc.), (2) your platform can deliver results in the timeline your program requires, and (3) you have in-house or partner expertise to interpret transcriptomics data without over-interpreting noise or batch effects.
Vendor resources like this one are useful for mapping the solution space but not for validating fit. Request independent comparisons between platforms if throughput claims matter to your timeline, and run pilot experiments on your own lead candidates before committing capital.